Replication Attempt: “Effect of BMAP-28 Antimicrobial Peptides on Leishmania Major Promastigote and Amastigote Growth: Role of Leishmanolysin in Parasite Survival”
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Aucune affiliation canadienne. Une base fondée sur la seule affiliation (le devis habituel) n'aurait jamais vu ce travail. C'est l'un des travaux qui justifient l'inversion de la base.
Le tri à trois modèles
les 1 000 travaux triés →Les trois modèles ont qualifié ce travail de métarecherche. Il appartient au noyau consensuel du domaine.
A direct replication submitted to the Reproducibility Initiative to independently validate a published result; framed as reproducibility work, though its immediate object is a specific biological claim.
This reports an attempted replication and independent validation of prior experiments, making reproducibility the object of study.
Independent replication attempt submitted to the Reproducibility Initiative; primary object is whether prior results replicate.
Résumé
This study describes an attempt to replicate experiments from the paper "Effect of BMAP-28 Antimicrobial Peptides on Leishmania major Promastigote and Amastigote Growth: Role of Leishmanolysin in Parasite Survival," which was submitted to the Reproducibility Initiative for independent validation. The cathelicidin bovine myeloid antimicrobial peptide 28 (BMAP-28) and its isomers were previously shown to have potent antiparasitic activity against Leishmania major. We tested the effectiveness of L-BMAP-28 and two of its isomers, the D-amino acid form (D-BMAP-28) and the retro-inverso form (RI-BMAP-28), in both unamidated and amidated forms, as anti-leishmanial agents against Leishmania major promastigotes in vitro. We observed that L-BMAP-28, as well as its D and RI isomers, demonstrate anti-leishmanial activity against L. major promastigotes in vitro. The inhibitory effect was lower than what was seen in the original study. At 2 µM of amidated peptides, the viability was 94%, 36%, and 66% with L-, D- and RI-peptides, versus 57%, 6%, and 18% in the original study.
Conservé avec la notice de tri, où il sert de preuve aux étiquettes ci-dessus.
La notice
- Revue
- PLoS ONE
- Thématique
- Research on Leishmaniasis Studies
- Domaine
- Medicine
- Établissements canadiens
- —
- Organismes subventionnaires
- University of California, San DiegoMcMaster UniversityBroad InstituteWashington University in St. LouisStanford Bio-XUniversity of MiamiOregon Health and Science University
- Mots-clés
- AmastigoteLeishmaniaAntimicrobialBiologyMicrobiologyLeishmania majorAntimicrobial peptidesPeptideAntiparasiticCathelicidinIn vitroAntiparasitic agentParasite hostingPharmacologyBiochemistryMedicine
- Résumé présent dans OpenAlex
- oui